

Special Issue

Advances in Serologic Assays for Vaccination Monitoring and Assessment of Immune Protection

Message from the Guest Editors

Serosurveillance has been utilized to assess the level of protection from vaccine-preventable diseases (VPDs) within a population; however, this method has not been widely adopted, and existing surveillance studies typically focus on single infectious diseases. An integrated approach has been recommended as a more effective way to conduct serosurveillance for VPDs. New multiplex bead assays (MBA) have been developed to facilitate multi-VPD studies. MBAs and point-of-care tests could be helpful for individuals wishing to determine their susceptibility to VPDs. This information could help individuals make informed decisions about vaccination. Consequently, greater access to and availability of antibody testing may help bridge the gap between personal choice and public health needs. Topics for the Special Issue include the following:

- Antibodies as markers of immunity to VPDs;
- Antibody tests for VPDs;
- Point-of-care tests for VPDs;
- Serosurveillance studies for VPDs.

Guest Editors

Dr. Paul D. Olivo

Department of Microbiology and Microbial Pathogenesis, Washington University Medical School, St. Louis, MO, USA

Dr. Randolph F.R. Rasch

College of Nursing, Michigan State University, East Lansing, MI 48824, USA

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/240463

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).